Podcast Summary: "The Cardiologist Who Stopped Prescribing Statins Explains the Real Cause of Heart Attacks"

The Dr. Hyman Show – ENCORE with Dr. Aseem Malhotra
Date: December 24, 2025
Host: Dr. Mark Hyman
Guest: Dr. Aseem Malhotra, UK Cardiologist, author of "The Statin-Free Life"

Episode Overview

In this provocative encore episode, Dr. Mark Hyman reconnects with renowned UK cardiologist Dr. Aseem Malhotra, who outlines his dramatic journey from being one of the top statin prescribers to becoming a leading critic of their widespread use in cardiovascular medicine. The discussion pulls back the curtain on the commercial influences shaping the science of cholesterol, heart disease, and statins, with Dr. Malhotra advocating for a drastic reevaluation of standard cholesterol treatment protocols. Together, they challenge listeners to rethink the true drivers of heart disease and the limitations of current medical dogma.

Key Discussion Points & Insights

1. Legal Vindication and Professional Repercussions

[03:33–15:06]

• Dr. Malhotra recounts his involvement in a high-profile UK defamation case (brought by Zoe Harcomb and Dr. Malcolm Kendrick) against the Mail on Sunday for labeling statin critics as "deadly propagandists".
  • Dr. Malhotra was named but declined to join the suit due to personal reasons and a commitment to public advocacy.
• Result: The High Court found in favor of the plaintiffs, affirming the legitimacy of raising questions about statin evidence.
• Malhotra faced severe backlash, including being fired from the NHS and effectively blacklisted—despite, as he notes, "never having a single patient complaint in a 23-year career" ([08:15]).

Memorable Quote:
"There are antibodies that have been developed against you because of your statin stance. People are allergic to you because of your opinion on statins."
— Dr. Malhotra ([08:15])

2. Commercial Distortion in Scientific Evidence

[09:37–14:53], [20:23–24:00], [32:57–36:00], [52:31–56:41], [80:05–81:57]

• Major academic promoters of statins (CTT, Cholesterol Trialists' Collaboration, Oxford) have received "hundreds of millions of dollars" from pharmaceutical interests ([09:37]).
• Host Dr. Hyman relays a revealing conversation:
  • “I can get $150 million to study a drug; I can’t get $5 to study lifestyle.”
    — Dr. Hyman ([10:22])
• Dr. Malhotra references John Ioannidis (Stanford), summarizing:
  • "The greater the financial and other prejudices in a given field, the less likely the research findings are to be true." ([11:37])
• Both hosts emphasize medicine as a social science, deeply susceptible to evolving evidence and commercial interests.
• Dr. Malhotra labels current medical knowledge as being "under commercial control, but most doctors don't know that." ([22:27])
• Dr. Hyman and Malhotra highlight the concept of “commercial determinants of health”—the strategies by which industry undermines true public health for profit ([80:05]).

Memorable Quote:
"Unless you correct commercial distortions of the scientific evidence, you won't fix health."
— Dr. Malhotra ([80:05])

3. Rethinking Cholesterol, Statins, and Heart Disease

[16:55–41:10]

• Statins are the most prescribed drugs worldwide—200 million to 1 billion are on them at any time ([16:55]).
• Dr. Malhotra’s investigation started with the obesity epidemic and flawed "low fat" dietary advice, leading to increased sugar/refined carb intake and more heart disease ([38:59]).
• His critical points:
  • Saturated fat intake is not clearly associated with heart disease. Lowering LDL cholesterol via drugs does not reliably prevent cardiovascular mortality.
  • The obsession with lowering LDL ("bad" cholesterol) is misplaced; underlying metabolic dysfunction, inflammation, and lifestyle factors are more important.
  • Statins’ small benefit in high-risk groups is likely due to anti-inflammatory, not cholesterol-lowering, effects.

Memorable Quote:
"If LDL cholesterol isn’t that important ... how do statins work? ... their anti-inflammatory and anti-clotting effects."
— Dr. Malhotra ([39:32])

4. Evidence Quality, Informed Consent, and Side Effects

[26:11–33:44], [60:00–64:00], [76:16–78:57]

• Statin benefits are marginal in real terms:
  • For secondary prevention (after a heart attack): Treat 83 people for 5 years to save 1 life; 1 in 39 will prevent a second heart attack ([27:29]).
  • For primary prevention (never had a heart attack): 1% reduction in risk at best, with no life extension ([27:52]).
• Most doctors and patients are unaware of these small absolute benefits; data is often presented in exaggerated “relative risk reduction” terms.
• Side effects (muscle pain, fatigue, cognitive issues, diabetes risk) are underreported due to trial design (pre-randomization run-in removes those who “don’t tolerate” the drug before formal study).
• Many prescribed statins in the real world stop taking them due to side effects (est. 20–50%) ([60:00]).

Memorable Quote:
"If you have to treat 89 people for five years to prevent one heart attack, 88 are getting no benefit—this is not how antibiotics work." — Dr. Hyman ([27:23])

5. LDL Cholesterol: Not the Whole Story

[42:38–52:12], [56:41–58:36], [65:36–68:00]

• Large scale studies (e.g., Framingham, BMJ analyses) show no reliable correlation between LDL cholesterol and risk of heart disease (when accounting for other metabolic factors).
• In people over 60, higher LDL is associated with lower all-cause mortality, possibly due to protective roles in the immune system ([48:49]).
• The real culprits: Insulin resistance and inflammation.
  • In patients with normal HDL and triglycerides, statins provide no benefit, even after a heart attack ([59:14]).
  • Low HDL and high triglycerides (often from excess sugar/starch and insulin resistance) are prime risk factors.

Memorable Quote:
"So if your triglycerides and HDL were good, even people who’ve had a heart attack, there was no benefit from the statin at all."
— Dr. Malhotra ([59:16])

6. Personalized Medicine & Who Really Needs Statins?

[64:46–72:00]

• There is heterogeneity: For most people, statins' marginal benefit does not outweigh risks. For those with familial hypercholesterolemia (FH) or other rare lipid disorders, risk is higher, but not uniformly so—the biggest differentiator is insulin resistance and LP(a) levels, not LDL alone ([68:45]).
• Dr. Malhotra recommends truly individualized, shared decision-making and heavy lifestyle focus rather than blanket statin prescriptions.
• Dr. Hyman underscores: “Not everybody is the same… Just because saturated fat is fine for most people doesn't mean it is for everyone.” ([64:46])

7. Root Cause & True Prevention: Lifestyle Over Pills

[73:43–85:08]

• Reversal of coronary artery disease is possible with diet, exercise, meditation, and profound lifestyle change.
  • Example: Raj Yoga meditation, healthy vegetarian diet, and relationships work in an Indian population showed marked arterial improvement within two years ([73:43]).
• Both hosts are not “anti-drug” but “pro-evidence” and “pro-truth,” seeking ethical, evidence-based medicine.
  • "Drugs for chronic disease rarely improve your quality of life… lifestyle changes come without side effects and improve your quality of life." — Dr. Malhotra ([84:48])

Notable Quotes (with Timestamps)

• On Industry Influence:
  "Medical knowledge is under commercial control, but most doctors don't know that." — Dr. Malhotra ([22:27])
• On Changing Beliefs:
  "The greater the financial and other prejudices in a given field, the less likely the research findings are to be true." — Dr. Malhotra, quoting John Ioannidis ([11:37])
• On Informed Consent:
  "Most patients with the 1% benefit say, 'Hold on a minute, I don't think that's that great, doc. What else can I do?' ... And that’s how medicine should be practiced." — Dr. Malhotra ([31:00])
• On Statin Trials:
  "Imagine they take the people out with side effects at the beginning and start the trial only once they’re gone … that’s fraud." — Dr. Malhotra ([76:16])
• On Root Cause:
  "We can't make America healthy again until you remove commercial distortions of the scientific evidence." — Dr. Malhotra ([80:00])
• On Lifestyle's Power:
  "Food is full of tens of thousands of molecules that regulate every aspect of your biology … understanding how to leverage that tool for healing is profound." — Dr. Hyman ([84:21])

Key Timestamps

• [03:33] Legal battle over statin criticism (vindication, backlash)
• [10:22] Pharma funding bias in research
• [16:55] Statins: prevalence, financial interests, limited effectiveness
• [27:23] Number needed to treat (NNT), ethical informed consent
• [39:32] Re-examining saturated fat, LDL, and heart disease
• [48:49] No relationship between LDL and mortality in over-60s
• [60:00] Side effect prevalence, real-world statin discontinuation
• [73:43] Lifestyle intervention and reversal of heart disease
• [80:05] Commercial determinants of health: root cause
• [84:21] Precision in food as medicine

Concluding Insights

• Statins can have a small benefit after a heart attack, but for most, the risks outweigh the modest gains.
• Cholesterol—especially LDL—is an overrated risk factor; root causes (insulin resistance, inflammation, lifestyle) are greater drivers of heart disease.
• Evidence is skewed both by industry influence and misleading presentation of statistics; true informed consent is rare.
• Lifestyle medicine is the most powerful tool for reversing and preventing chronic disease.
• Empowering patients to understand their metrics and risks—rather than prescribing by rote—is fundamental to ethical, effective healthcare.

Resources & Further Reading:

• Dr. Aseem Malhotra: draseem.com, "The Statin-Free Life", nofarmfilm.com
• Dr. Hyman: "Eat Fat, Get Thin", Function Health
• BMJ, NNT.com, "Why Most Published Research Findings Are False" (Ioannidis)
• Commercial Determinants of Health (WHO report)

Final Thought:
"I'm not anti-pharma, I'm pro-ethical evidence-based medical practice."
— Dr. Aseem Malhotra ([82:56])